Współczesna Onkologia

Full text

3/2026 vol. 30
Editorial

Salivary gland-like carcinomas of the breast: true hormone receptor heterogeneity or diagnostic heterogeneity

Semir Vranić 1
,
Zoran Gatalica 2
,
Piotr Czapiewski 3, 4, 5

  1. College of Medicine, QU Health, Qatar University, Doha, Qatar

  2. Reference Medicine, Phoenix, Arizona, United States of America

  3. Institute of Pathology, Städtisches Klinikum Dessau, Dessau-Roßlau, Germany

  4. Institute of Pathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

  5. Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland

Contemp Oncol (Pozn) 2026; 30 (3): 186–188

DOI: https://doi.org/10.5114/wo.2026.166003
Data publikacji online: 2026/11/09
Article file
Salivary gland-like.pdf
  1. World Health Organization Classification of Tumours Editorial Board. Breast Tumours. 6th ed. International Agency for Research on Cancer, Lyon 2026.
  2. Ajkunic A, Skenderi F, Shaker N, Akhtar S, Lamovec J, Gatalica Z, et al. Acinic cell carcinoma of the breast: A comprehensive review. Breast 2022; 66: 208-216.
  3. Lu Y, Kong X, Wang X, Zhang W, Li Y, Dong H, et al. Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and systematic review. Cancer Treat Rev 2024; 131: 102830.
  4. Jones VM, Bachert SE. When three negatives equal a positive: molecular updates of triple-negative breast carcinomas with favorable prognoses. Semin Diagn Pathol 2026; 43: 151028.
  5. Qi M, Gao S, Zhang Z, Lang R, Huang Z, Wang J, et al. Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit. Breast Cancer Res Treat 2025; 210: 451-461.
  6. Foo CY, Sehrawat O, Puri A, Haque W, Teh BS. Clinicopathologic features, treatment patterns and survival outcomes of acinic cell carcinoma of the breast: a national cancer database analysis. Breast Cancer Res Treat 2026; 218.
  7. Skenderi F, Babu GR, Glamoclija U, Veledar E, Gatalica Z, Lamovec J, et al. Acinic cell carcinoma of the breast: a population-based clinicopathologic study. Cancer Rep (Hoboken) 2025; 8: e70357.
  8. Tluli O, Abujbara MM, Almaraghi EA, Tluli D, Babu GR, Vranic S. A clinicopathologic and survival analysis of mucoepidermoid carcinoma of the breast. Contemp Oncol (Pozn) 2026; 30: 157-169.
  9. Akbulut S, Dalda Y, Ivanova M, Fusco N. Mucoepidermoid carcinoma of the breast: a systematic review of clinicopathologic, immunohistochemical, and molecular features. World J Surg 2025; 49: 2630-2643.
  10. Ding X, Sun H. Breast mucoepidermoid carcinoma: a report of two cases. Ann Clin Lab Sci 2026; 56: 344-349.
  11. Ch’ng ES. Prognosis of primary breast salivary gland-type carcinoma: a propensity score-matching analysis with invasive carcinoma of no special type based on the SEER database for years 2010–2020. Breast Cancer 2024; 31: 496-506.
  12. Sanli AN, Tekcan Sanli DE, Altundag MK, Aydogan F. Secretory carcinoma of breast: a population-based study. Am Surg 2024; 90: 252-260.
  13. Gong P, Xia C, Yang Y, Lei W, Yang W, Yu J, et al. Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast. Sci Rep 2021; 11: 14738.
  14. Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol 2016; 113: 721-725.
  15. Zhao YY, Ge HJ, Yang WT, Shao ZM, Hao S. Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients. Breast Cancer Res Treat 2024; 203: 543-551.
  16. Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019; 32: 147-153.
  17. Marchio C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 2019; 30: 1417-1427.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications